Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | CPX-351: liposomal daunorubicin/cytarabine for AML

Jorge Cortes • 17 Jun 2020
ESH AL 2020
Acute Myeloid Leukemia Leukemia Cytarabine Daunorubicin

Jorge Cortes, MD, Georgia Cancer Center, Augusta University, Augusta, GA, discusses the use of CPX-351, a liposomal formulation of cytarabine and daunorubicin, in patients with newly diagnosed, high-risk acute myeloid leukemia (AML). Specifically discussed are the results from a Phase II trial (NCT02286726) of CPX-351 in patients with acute myeloid leukemia at high-risk for induction mortality. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jorge Cortes

2:12
Key emerging trials in CML and the importance of improving treatment-free remission rates
Jorge Cortes • 7 Sep 2023
2:09
Social determinants of health & their impact on patients with hematological malignancies
Jorge Cortes • 7 Sep 2023
1:57
Post-hoc analysis of OPTIC: patient responses to ponatinib by T315I mutational status
Jorge Cortes • 7 Sep 2023
2:21
Exciting updates in the field of CML: disease pathophysiology & novel agents
Jorge Cortes • 7 Sep 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals